Related Experiment Video
Updated: May 3, 2026
Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
Published on: February 2, 2024
Taxanes: impact on pancreatic cancer
E Gabriela Chiorean1, Daniel D Von Hoff
1aDepartment of Medicine, University of Washington, Seattle, Washington bTranslational Genomics Research Institute (TGen)/Virginia Piper Cancer Center, Scottsdale, Arizona, USA.
Abstract:
Taxanes are core therapeutic components for several advanced malignancies, and have been studied extensively in pancreatic adenocarcinomas with mixed results. Although the triplet combination FOLFIRINOX improves outcomes for patients with metastatic disease, it is compounded by significant toxicity, and novel regimens, rationally designed and based on thorough mechanistic activity on the tumor targets, are clearly needed. Solvent-based taxanes, docetaxel and paclitaxel, have little activity as single agents, but combinations with fluoropyrimidines and gemcitabine show efficacy, albeit they have not undergone testing in phase III trials. Pancreatic cancer is characterized by an abundant desmoplastic, fibroinflammatory and hypoperfused stroma, which has been blamed for its overall chemoresistance. Nanoparticle bound paclitaxel (nab-paclitaxel) has been pharmacologically designed as a novel water-soluble agent, with improved therapeutic index compared with the cremophor-based formulation, capable of achieving higher systemic exposure. In preclinical systems, when combined with gemcitabine, nab-paclitaxel increased intratumoral gemcitabine delivery, possibly due to inducing stromal 'collapse' and through inhibition of the gemcitabine-catabolizing enzyme cytidine deaminase. Most recently, the combination of nab-paclitaxel and gemcitabine demonstrated significant survival benefit with good tolerability in metastatic pancreatic cancer in the phase III trial MPACT, and now represents one of the gold-standard regimens for this disease. Although taxanes are overall potent chemotherapeutics for various cancers, it is clear that for meaningful results in pancreatic adenocarcinomas, rationally designed combinations and novel technologies for drug delivery are likely to be most successful.
Insights
Novel nanoparticle-bound paclitaxel (nab-paclitaxel) combined with gemcitabine offers improved survival and tolerability for metastatic pancreatic cancer patients. This combination represents a new gold standard, addressing chemoresistance in pancreatic adenocarcinomas.
Area of Science:
- Oncology
- Pharmacology
- Drug Delivery Systems
Background:
- Taxanes are crucial in treating advanced cancers but show mixed results in pancreatic adenocarcinomas.
- Existing FOLFIRINOX regimens improve outcomes but cause significant toxicity, necessitating novel therapeutic strategies.
- Pancreatic cancer's dense stroma contributes to chemoresistance, limiting the efficacy of conventional treatments.
Purpose of the Study:
- To evaluate the efficacy and safety of nanoparticle-bound paclitaxel (nab-paclitaxel) in combination with gemcitabine for metastatic pancreatic cancer.
- To explore the mechanistic basis for improved drug delivery and efficacy of nab-paclitaxel in the pancreatic tumor microenvironment.
- To establish a new, rationally designed therapeutic regimen with improved tolerability and survival benefit.
Main Methods:
- Preclinical studies investigating the interaction of nab-paclitaxel and gemcitabine in pancreatic cancer models.
- Phase III clinical trial (MPACT) assessing the survival benefit and tolerability of the nab-paclitaxel plus gemcitabine combination.
- Pharmacological analysis of nab-paclitaxel's improved systemic exposure and intratumoral delivery compared to solvent-based taxanes.
Main Results:
- Nab-paclitaxel, a novel water-soluble formulation, demonstrated enhanced therapeutic index and systemic exposure.
- Combination therapy with nab-paclitaxel and gemcitabine showed preclinical evidence of increased intratumoral gemcitabine delivery.
- The MPACT trial confirmed significant survival benefit and good tolerability for metastatic pancreatic cancer patients treated with nab-paclitaxel and gemcitabine.
Conclusions:
- The combination of nab-paclitaxel and gemcitabine represents a significant advancement in metastatic pancreatic cancer treatment.
- Novel drug delivery technologies, like nanoparticle-bound formulations, are key to overcoming chemoresistance in pancreatic adenocarcinomas.
- Rationally designed combination therapies hold promise for improving outcomes in challenging malignancies like pancreatic cancer.
